The third alteration linked with improved survival in glioma is hypermethylation of the promoter region of MGMT, a gene encoding a DNA repair enzyme, whose low level has been associated with increased sensitivity to the alkylating agents, such as temozolomide (TMZ), used in glioma therapy [12]. Here, MGMT is linked to central nervous system cancer.